²Ä 156 ´Á 2006-06-29

·|ij³ø¾É
°ê®a½Ã¥Í¬ã¨s°|²Ä¥|©¡²Óµß°ò¦]½Õ±±»P­P¯f¾÷Âà¬ã°Q·|¬ö­n

½t°_
¥Á°ê¤E¤Q¦~®L¤Ñ¤§¦~«×«D¥¿¦¡²Óµß¬ã°Q·|ªº»E·|¸Ì¡A¼B¥@ªF±Ð±Â´£¨ì¥Ñ°ê®a½Ã¥Í¬ã¨s°|©ÒÁ|¿ìªº¬ã°Q·|¤¤¿W¯Ê²Óµß¾Ç»â°ì¡C¨Æ¹ê¤W¡A±q¨Æ²Óµß¾Ç¬ã¨s¤§¥»°ê¾ÇªÌ¤w³v¤é¼W¦h¡AÀ³¥i½Ð°ê®a½Ã¥Í¬ã¨s°|¨ó§UÁ|¿ì¨ã°ê»Ú¤Æ¤§²Óµß¬ã°Q·|¡C©ó¬O¡A¦b´X¦ì±Ð±Âªº¿n·¥µ¦¹º¤§¤U¡A©ó¤E¤Q¤@¦~¥|¤ë¤G¤Q¤»¤é¥H¤Î¤G¤Q¤C¤é¨â¤Ñ¡A¦b®ç¶é¿¤Às¼æ¶m§»ùÖ´÷±æ¾Ç²ß¤¤¤ßÁ|¿ì¤F­º©¡ªº¡u²Óµß°ò¦]½Õ±±»P­P¯f¾÷Âà¬ã°Q·|¡v¡C¥Ñ©ó²Ä¤@©¡«Y­º«×¹Á¸ÕÁpô°ê¤º±q¨Æ»P²Óµß°ò¦]½Õ±±»P­P¯f¾÷Âà¬ÛÃö¬ã¨s¤§¾ÇªÌ¦P»E¤@°ó¥æ´«¸gÅç»P¤ß±o¡A¬G¼È¥¼ÁܽХ~°ê¾ÇªÌ°Ñ»P¡C·|«á©Ò¦³°Ñ»PªÌ¤ÏÀ³¼ö¯P¡A¨Ã¨M©w¤@¦~«áÄò¿ì¦¹¬ã°Q·|¡CµM¦]SARS¤§µo¥Í¡A²Ä¤G©¡¤§¡u²Óµß°ò¦]½Õ±±»P­P¯f¾÷Âà¬ã°Q·|¡v©µ¦Ü¤E¤Q¤T¦~¥|¤ë¤G¤Q¥|¤é¥H¤Î¤G¤Q¤­¤é¨â¤Ñ©ó¦P¤@¦aÂIÁ|¦æ¡C¨ä«á²Ä¤T©¡¤Î²Ä¥|©¡¤§¡y²Óµß°ò¦]½Õ±±»P­P¯f¾÷Âà¬ã°Q·|¡z¦]°ê®a½Ã¥Í¬ã¨s°|©ó¦Ë«n«Ø°|§¹¦¨¡A¬G¤À§O©ó¤E¤Q¥|¦~¥|¤ë¤T¤Q¤é¦Ü¤­¤ë¤@¤é¡A¤E¤Q¤­¦~¥|¤ë¤G¤Q£¸¤é¦Ü¤G¤Q¤G¤é©ó¦Ë«n°ê®a½Ã¥Í¬ã¨s°|°|°ÏÁ|¦æ¡C¦¹¤G¦¸·|ij¬Ò¥Ñ¤ýÀA°ó¡B¦óº§º¬¡B§d«T©¾¡B­J¤p´@¡B±i®Ì·ß¡B´^¼z¬Â¡B¼B¥@ªF¡B¿à«H§Óµ¥¾á¥ôÄw³Æ©e­û¡A¨Ã¥Ñ²Ä¤G©¡°_¨C¦¸·|ij¬ÒÁܽШâ¦W°ê¥~ª¾¦W¾ÇªÌ»P·|¡A©Ò¦³¤fÀY¤Î®Ñ­±³ø§i¬Ò¥H­^¤åµoªí¡C

·|ij¤º®e·§­z
¥»©¡¬ã°Q·|°Ñ¥[ªÌ¬ù70¤H¡]¥]¬A11¦W´£¥X¬ã¨s¦¨ªGªº³Õ¤h¯Z¾Ç¥Í¤Î¬ã¨s¾ÇªÌ¡^¡A¥]§t¤T­Ó¥DÃD¡A¤À§O¬°¡u±J¥D»P²Óµß¤§¬Û¤¬§@¥Î¡]Host-Bacterial Interaction¡^¡v¡A¡u²Óµß­P¯f¾÷Âà¡]Bacterial Pathogenesis¡^¡v©M¡uµ²ºc¥Íª«¾Ç¡]Structure Biology¡^¡v¡C²Ä¤@­Ó¥DÃD§t¦³¤@­Ó¯S§OºtÁ¿©M¤­­Ó¤fÀY³ø§i¡F²Ä¤G­Ó¥DÃD§t¦³¤T­Ó¤fÀY³ø§i¡F²Ä¤T­Ó¥DÃD«h§t¦³¤@­Ó¯S§OºtÁ¿©M¤T­Ó¤fÀY³ø§i¡C¨C¦¸ªº¯S§OºtÁ¿®É¶¡¬ù1¤p®É¡A¦Ó¤fÀY³ø§i«h¬°25¤ÀÄÁ¡C

¦b²Ä¤@­Ó¥DÃD¡u±J¥D»P²Óµß¤§¬Û¤¬§@¥Î¡]Host-Bacterial Interaction¡^¡v·í¤¤¡A­º¥ý¥Ñ¬ü°ê«¢¦ò¤j¾ÇªºEric Rubin±Ð±Â¡]Department of Immunology and Infectious Diseases, Harvard School of Public Health, USA¡^µ¹¤©¤@³õ¯S§OºtÁ¿¡A¨äÁ¿ÃD¬°¡G§Q¥ÎÂà¦ì¤l³¡¦ìÂø¥æ§Þ³N(Transposon Site Hybridization, TraSH)¬ã¨s¤ÀªK±ìµß(Mycobacterium)¤§°ò¦]Åé¡CRubin±Ð±Â­º¥ý§Q¥ÎÂà¦ì¤l¬ðÅܪk«Ø¥ß¤F¤ÀªK±ìµß¤§¬ðÅÜ®è¡A¨C¤@¬ðÅÜ®è¶È±a¤@­ÓÀH·N´¡¤J¤§Âà¦ì¤l¡A¦A§Q¥ÎDNA·L°}¦C(microarrays)¤j¶q©w¥XÂà¦ì¤l´¡¤J¤§³¡¦ì¡A¦]¤§µo®i¥XÂà¦ì¤l³¡¦ìÂø¥æ§Þ³N¡A¦¹§Þ³N¥i¥Î¨Ó¤ñ¸û¥X­þ¨Ç°ò¦]¬°²Óµß¥Íªø©Ò¥²»Ý¡A¬G¦ÓµLÂà¦ì¤l¤§´¡¤J¡CRubin±Ð±Â¤]§Q¥Î³J¥Õ½èÅé¾ÇŲ©w¤F­þ¨Ç°ò¦]»P²Óµß¤§¬r¤O¦³Ãö¡A¨ä¤¤·sµo²{¤§ESX-1¥ç¬°³J¥Õ½è¤Àªc¨t²Î¤§­«­n¦¨¥÷¡C

±µµÛ¡A¤¤¥¡¬ã¨s°|´Óª«º[·L¥Íª«¾Ç¬ã¨s©Ò¶ÀµqÞ±³Õ¤hµoªíTzs³J¥Õ½è¬°´Óª«²ÓµßAgrobacterium tumefaciens¥Íªø©Ò¥²¶·¡C¦¨¤j·L¥Íª«¤Î§K¬Ì¾Ç¬ã¨s©ÒªL¥H¦æ±Ð±Â³ø§i¤FÃì²yµß¤§¤ÆÁw©Ê¥~¬r¯À(Streptococcal pyrogenic exotosin B)¥iÂǥѳJ¥Õ½èS¤§¤Á³Î¨Ó§í¨î¥¨¾½²Ó­M²M°£­ä¤`¤§²Ó­M¡C¥x¤j·L¥Íª«¾Ç¬ì¸ë´º¤s±Ð±Â¤¶²Ð¤FÃì²yµß¤§¸²µå¿}Âಾ»Ã¯À(Glucosyltransferase)»P¤º¥Ö²Ó­M(endothelial cell)¤§¥æ¤¬§@¥Î¹ï·P¬V©Ê¤ß¤º½¤ª¢(infective endocarditis) ¤§§K¬Ì­P¯f¦]¡Cªø©°¤j¾Ç·L¥Íª«¤Î§K¬Ì¾Ç¬ìÁ¸h¯]±Ð±Â¤¶²Ð¤F¦b§J¹p§B¤óªÍª¢±ìµß(Klebsiella pneumoniae)·P¬V¤§¤HÃþ¨xÀù²Ó­M®èHepG2¨ä¤¤¤§Mitogen activated protein (MAP) kinase ·|¬¡¤Æ¡C³Ì«á¡A¶§©ú¤j¾Ç·L¥Íª«¤Î§K¬Ì©Ò³\¸UªK±Ð±Â³ø§i¤F¥X¦å©Ê¤j¸z±ìµßEnterohemorrhagic E. coli O157:H7¤§­P¯f®qÀ¬(pathogenicity island)¤¤°ò¦]ªí²{¤§½Õ±±¡C

¦b²Ä¤G³¡¥÷¡u²Óµß­P¯f¾÷Âà (Bacterial Pathogenesis)¡vªº¥DÃD·í¤¤¡A­º¥ý¥Ñ¦¨¤j·L¥Íª«¤Î§K¬Ì¾Ç¬ã¨s©Ò¦óº§º¬±Ð±Â³ø§i¤F²Ä¤G¥Íª««¬³Ð¶Ë©·µß²Åµß®è¤¤(Biotype 2 Vibrio vulnificus) ¨ã¦³¬r¤O¤§½èÅé¨ä®Ö¥Ì»Ä§Ç¦C¤ÀªR¤Î¯S©Ê¤§¬ã¨s¡C±µµÛ¡A¤¤¥¡¬ã¨s°|´Óª«º[·L¥Íª«¾Ç¬ã¨s©Ò½²汮Às³Õ¤hµoªí¦p¦ó§Q¥Î°°³æ­M²ÓµßPseudomonas putida YLFP14¨Ó±±¨î²¢´Ô¤§²Óµß´³ÂI¯f¤Î¨ä¬ÛÃö¤§¾÷¨î¡C¦PÄݸӳæ¦ì¤§¿àº¸珉±Ð±Â«h³ø§i¤F¥H³J¥Õ½èÅé¾Ç¤ÀªR¤F­þ¨Ç°ò¦]»P´Óª«²ÓµßAgrobacterium tumefaciens¤§¬r¤O¦³Ãö¡C

¦b²Ä¤T³¡¥÷¡uµ²ºc¥Íª«¾Ç¡]Structure Biology¡^¡vªº¥DÃD¤¤¡A­º¥ý¥Ñ¬ü°êScripps¬ã¨s©ÒªºJames A. Hoch±Ð±Â¡]Department of Molecular and Experimental Medicine, The Scripps Research Institute, USA¡^µ¹¤©¤@³õ¯S§OºtÁ¿¡C¨äÁ¿ÃD¬°¡G²Óµßªº¨âºØ¤À¤l°T®§¶Ç¾É¨t²Î¤¤¤À¤l¯S²§©Ê¤§ºt¤Æ¡C²Óµßªº¨âºØ¤À¤l°T®§¶Ç¾É¨t²Î¥]§t¤@­Ó·P´ú°T®§ªºHistidine kinase¤Î¤@­Ó¤ÏÀ³½Õ±±Âà¿ý¦]¤l¡A¥i±NÀô¹Ò¤Î²Ó­Mªº°T®§Âà´«¦¨°ò¦]¤§ªí²{©Î¦æ¬°¤§§ïÅÜ¡C¦¹¨âºØ¤À¤l¤§¶¡ªº¥æ¤¬§@¥Î¦³¨ä¯S²§©Ê¡AHoch±Ð±Â§Q¥Î·sªº¼Æ¾Ç¤èªk¤ÀªR°ò¦]¸ê®Æ¡A¦A¦X¨Ö¤À¤l¤§´¹Åéµ²ºc¡AÂǦ¹¥HÀ˵ø¦¹¨âºØ¤À¤l¤§¶¡ªº¥æ¤¬§@¥Î¡AHoch±Ð±Â©Ò«Ø¥ßªº¤èªk¥iÅã¥Ü¦b¨â¤À¤l¥æ¤¬§@¥Îªºªí­±¦p¦óºt¤Æ¥X¯S²§©Ê¡A¥H¤Î¦p¦óµo²{­t³d¿ï¾Ü©ÊªºÓi°ò»Ä¡C±µµÛ¥Ñ¤¤¥¡¬ã¨s°|¥Í¤Æ©ÒªL«T§»³Õ¤h¤¶²Ð«Õªù±ìµß(Helicobacter pylori)¤§£\1,3-Fucosyltransferase¨äCºÝ¨M©w¤F¦¹»Ã¯À¤§µ²ºc¤Îí©w©Ê¡C¤¸´¼¤j¾Ç¥Íª«¬ì§Þ¤Î¥Íª«¸ê°T¬ã¨s©Òªº±d¥@¦°±Ð±Â¡A¤¶²Ð¤F»PÂ×­ì¯À¯×ªÕ»Ä¦X¦¨¦³Ãöªº°ò¦]¤§¬ã¨s¡Aªø©°¤j¾Ç·L¥Íª«¤Î§K¬Ì¾Ç¬ìªº§d©Ó¦t³Õ¤h¤¶²Ð³J¥Õ½è¦X¦¨»Ã¯À½Æ¦Xª«¤§§Î¦¨¡A¬°¦X¦¨Â×­ì¯À©Ò¥²¶·¡C

¦¹¦¸¬ã°Q·|ÁÙ¦³¤Q£¸­Ó¾À³ø®i¥Ü¬ã¨s¦¨ªG¡A¾À³øªº¤º®e¥ç²[»\¤W­z¤T­Ó¥DÃD¡A¬ã¨sªº¤º®e¤]¬Û·íºëªö¡C

¦@ÃÑ»P¨Mij
¤@¡B¥»¬ã°Q·|¤µ«áÄ~Äò¨C¦~Á|¦æ¤@¦¸¡A¨Ã³q¹L¥Ñªø©°¤j¾Ç·L¥Íª«¤Î§K¬Ì¾Ç¬ìÁ¸h¯]±Ð±Â¾á¥ô¤U©¡Äw³Æ©e­û·|¥l¶°¤H¡C

¤G¡B¦p¦P©¹¦~¡A°Ñ¥[ªÌ¤´§Æ±æ¯à°÷¶}©ñ§ó¦h¤H³ø¦W¡A¥H¹Å´f§ó¦hºÓ³Õ¤h¯Z¾Ç¥Í¡A¨Ã¼W¶i¸ó»â°ì¬ã¨s¤H­û¶¡¤§¤¬¬Û¥æ¬y¡C°ê¥~¤§¬ã¨sªÌ¤è­±¡A§Æ±æ¥iÂX¤Î¦Ü¾Fªñ¦pÁú¡B¤é¦U°ê¤§¾ÇªÌ¡AÁܽШä§@¤fÀY³ø§i©Î´£¥X¾À³ø½×¤å¡C

¤T¡B°ê¤º¦³Ãö·P¬Vªº¬ã¨s¬Û·í¦h¡A¥¼¨Ó¥i¦hÁÜÁ{§ÉÂå®v°Ñ»P¡C¥t§ÜÃĩʪº¬ã¨s¥ç¥i¦C¤J¤U¦¸ªº¥DÃD¡C
¡m¤å/¹Ï¡G°|¥~³B´£¨Ñ¡F¤å¡G­J¤p´@¡]¶§©ú¤j¾Ç·L¥Íª«¤Î§K¬Ì¾Ç¬ã¨s©Ò±Ð±Â¡^¡F¹Ï¡G»P·|¤H­û¦X¼v¡A«e±Æ¥ª°_¬°³¯®¶¶§¥N²z³Bªø¡A³\¸UªK±Ð±Â¡ADr. Eric Rubin¡ADr. James A. Hoch¡A­J¤p´@±Ð±Â¡n